Timely news, given the current discussion around upholding an interim decision to classify adrenaline-based intranasal preparations as Schedule 3 medicines.
End of content
No more pages to load
Timely news, given the current discussion around upholding an interim decision to classify adrenaline-based intranasal preparations as Schedule 3 medicines.
End of content
No more pages to load